Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 8/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18053948 | 0.90 | MAPT (0.70) | POLBMAPTRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL18053871 | 0.88 | POLB (0.68) | POLBMAPTRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL521371 | 0.86 | POLB (1.00) | POLBMAPTRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL29437404 | 0.86 | POLB (1.00) | POLBMAPTRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL23132947 | 0.84 | POLB (0.74) | POLBMAPTRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL18053939 | 0.83 | POLB (0.68) | POLBMAPTRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL18058676 | 0.83 | POLB (0.68) | POLBMAPTRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL31607933 | 0.83 | POLB (0.68) | POLBMAPTRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL26705462 | 0.83 | MAPT (0.63) | POLBMAPTRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL23109102 | 0.83 | POLB (0.72) | POLBMAPTRAB9ASMN1; SMN2CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | POLB 1657/4885MAPT 1236/4885RAB9A 3462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.